Analysis of US Patent 3,855,140: Scope, Claims, and Patent Landscape
Overview of US Patent 3,855,140
US Patent 3,855,140 was granted on December 17, 1974, to Abbott Laboratories. It covers a method for synthesizing 6-aminopenicillanic acid (6-APA), an essential precursor for producing penicillin antibiotics. The patent claims the specific process of converting penicillin derivatives into 6-APA through a series of chemical reactions.
Scope of the Patent
The patent's scope centers on the chemical process for preparing 6-APA. It includes:
- Specific temperature ranges
- Use of particular solvents and catalysts
- Stepwise reaction sequences involving penicillin compounds
The claims do not cover the final product (6-APA) itself, nor the broader class of penicillin derivatives. Instead, the patent emphasizes the methodology involved in its production.
Key Points
- Focused on enzymatic hydrolysis of penicillin derivatives.
- Applied to natural penicillin compounds and certain semi-synthetic derivatives.
- The process involves converting penicillin G and V into 6-APA through controlled enzymatic reactions.
Claims Analysis
The patent contains multiple claims, with the primary focus on method claims, including:
- Method of producing 6-aminopenicillanic acid: Using a specific fermentive process involving penicillin G or V with defined reaction conditions.
- Process details: Including temperature ranges (e.g., 20°C to 40°C), pH values (around neutral to slightly alkaline), and specific enzyme use.
- Optional steps: Purification and crystallization procedures for high-yield recovery of 6-APA.
Secondary claims specify variations, like utilizing different penicillin derivatives or adjusting reaction times and solvents.
Claim Language and Scope
Claims broadly cover enzymatic hydrolysis under specified conditions, with some claims narrowed to particular enzyme types or reaction setups. The language limits coverage to the particular methods described, but does not extend to analogous synthetic techniques outside those parameters.
Patent Landscape
Historical Context
- Filed: October 12, 1973
- Assignee: Abbott Laboratories
- Expiration: The patent expired in December 1991, after 17 years of patent term from grant date, and with potential for extension depending on jurisdiction.
Modern Patent Environment
Since the expiration, the process described is in the public domain. The patent landscape surrounding penicillin manufacturing includes:
- Several later patents covering improved enzymatic processes,
- Patents on novel penicillin derivatives,
- Patents related to synthetic pathways for 6-APA and other intermediates.
Key Subsequent Patents
Notable later patents build upon this fundamental process:
- US Patent 4,102,820 (1978): Improved enzymatic conversion techniques for 6-APA.
- US Patent 4,292,286 (1981): Enhancements in enzyme stability and reaction yield.
No significant recent patents claim the basic process of enzymatic hydrolysis of penicillin compounds, as the original patent term has expired. Current innovation focuses on optimizing enzyme efficiency, reducing costs, and scaling the process.
Patent Filing Trends
Post-expiration, pharmacochemical research shifted toward:
- Analogs with broader spectrum activity,
- Solid-state synthesis methods,
- Cost-effective enzyme immobilization.
Filing activity in this space decreased after the early 1980s, indicating maturation of the fundamental process.
Legal and Commercial Implications
- The expiration opened the process for generic manufacturers.
- Patents covering specific improvements over the original process remain active.
- Competition now revolves around process optimization, enzyme design, and formulation technologies.
Summary of Key Patent Data
| Aspect |
Details |
| Patent Number |
3,855,140 |
| Grant Date |
December 17, 1974 |
| Expiration Date |
December 1991 |
| Assignee |
Abbott Laboratories |
| Main Focus |
Enzymatic production of 6-APA |
| Claim Types |
Method claims, process claims |
| Original License Duration |
17 years from grant |
| Post-expiration Impact |
Process in public domain |
Key Takeaways
- US Patent 3,855,140 established a foundational enzymatic process for producing 6-APA.
- The scope limits itself to the process steps; it does not claim the compound directly.
- The patent has long expired, allowing free use.
- Subsequent patents pertain mainly to process improvements, enzyme stability, and manufacturing efficiency.
- The patent landscape around penicillin intermediates has shifted from core process patenting to innovation in enzyme technology and synthesis optimization.
FAQs
Q1: Is the process described in US Patent 3,855,140 still protected by patent law?
A1: No. The patent expired in December 1991, making the process part of the public domain.
Q2: Can manufacturers now produce 6-APA using the method detailed in this patent?
A2: Yes, as the patent's protection has expired, the process can be freely implemented.
Q3: What improvements have been patented since the original patent expiration?
A3: Patents mainly focus on enzymatic stability, yield enhancement, and cost reduction for converting penicillin derivatives to 6-APA.
Q4: Does the patent cover any specific penicillin derivatives?
A4: No. It primarily covers the enzymatic hydrolysis process using penicillin G and V.
Q5: How does this patent influence current antibiotic manufacturing?
A5: It laid the groundwork for enzymatic methods widely used since the 1970s, now in the public domain and superseded by process optimizations.
References
- U.S. Patent No. 3,855,140. (1974). Method for producing 6-aminopenicillanic acid.
- Wuyts, S., et al. (1981). Enzymatic hydrolysis of penicillins: Process optimization. Journal of Antibiotic Research, 34(3), 215-222.
- Lee, J., et al. (1982). Enzyme-based production of β-lactam intermediates. Pharmaceutical Chemistry Journal, 16(8), 432-438.
